Search Within

Neeta Pandit-Taskar

  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (16)
Groups
  1. Department of Medicine (43)
  2. Hematologic Malignancies, Division of (43)
  3. Molecular Imaging and Therapy Service (43)
  4. Radiology, Department of (43)
  5. GSK Faculty (27)
  6. Center for Hematologic Malignancies (26)

More Groups

People
  1. Steven Larson (23)
  2. Jorge Carrasquillo (15)
  3. Chaitanya Divgi (12)
  4. Howard Scher (11)
  5. Michael Morris (11)
  6. Susan Slovin (11)

More People

Years
  1. 2024 (2)
  2. 2023 (3)
  3. 2022 (3)
  4. 2021 (2)
  5. 2019 (2)
  6. 2016 (1)

More Years

Publications
  1. Blood (13)
  2. Journal of Clinical Oncology (12)
  3. Clinical Cancer Research (5)
  4. Journal of Nuclear Medicine (4)
  5. Cancer (2)
  6. European Journal of Nuclear Medicine and Molecular Imaging (2)

More Publications

Publishers
  1. American Society of Hematology (13)
  2. American Society of Clinical Oncology (12)
  3. American Association for Cancer Research (6)
  4. Society of Nuclear Medicine (4)
  5. Springer (3)
  6. Wiley Blackwell (2)

More Publishers

Results (43)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of docetaxel and (153)Sm repetitively administered for castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Amodio, A. J.; Gignac, G. A.; Flatts, E.; Slovin, S.; Solit, D.; Rathkopf, D.; Larson, S.; Scher, H. I.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I trial of the targeted alpha-particle nano-generator actinium-225 (Ac-225)-HuM195 (Anti-CD33) in acute myeloid leukemia (AML)
    Meeting Abstract

    Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S.; Frattini, M. G.; Larson, S. M.; Scheinberg, D. A.
    Blood (2007)

    Fulltext@MSK | Save
  • Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors
    Journal Article

    Morris, M. J.; Pandit-Taskar, N.; Divgi, C. R.; Bender, S.; O'Donoghue, J. A.; Nacca, A.; Smith-Jones, P.; Schwartz, L.; Slovin, S.; Finn, R.; more...
    Clinical Cancer Research (2007)

    Fulltext@MSK | Save
  • Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma
    Journal Article

    Iwamoto, F. M.; Schwartz, J.; Pandit-Taskar, N.; Peak, S.; Divgi, C. R.; Zelenetz, A. D.; Humm, J.; Abrey, L. E.
    Cancer (2007)

    Fulltext@MSK | Save
  • Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions
    Meeting Abstract

    Zelenetz, A. D.; Noy, A.; Pandit-Taskar, N.; Scordo, M.; Rijo, I.; Zhou, Y.; O'Donoghue, J. A.; Divgi, C.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Alpha-particle immunotherapy for acute myeloid leukemia (AML) with bismuth-213 and actinium-225
    Meeting Abstract

    Jurcic, J. G.; McDevitt, M. R.; Pandit-Taskar, N.; Divgi, C. R.; Finn, R. D.; Sgouros, G.; Apostalidis, C.; Chanel, S.; Larson, S. M.; Scheinberg, D. A.
    Cancer Biotherapy and Radiopharmaceuticals (2006)

    Fulltext@MSK | Save
  • Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP chemotherapy for mantle cell lymphoma is a safe and highly effective regimen
    Meeting Abstract

    Zelenetz, A.; Donnelly, G.; Pandit-Taskar, N.; Humm, J.; Divgi, C.
    Annals of Oncology (2005)

    Fulltext@MSK | Save
  • Early safety and efficacy analysis of a phase II study of sequential R-CHOP and Yttrium-90 ibritumomab tiuxetan (Zevalin((R))) for elderly high risk patients with untreated DLBCL
    Meeting Abstract

    Hamlin, P. A.; Moskowitz, C. H.; Wegner, B. C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Dumitrescu, O.; Palomba, M. L.; Horwitz, S. M.; O'Connor, O. A.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
    Journal Article

    Morris, M. J.; Divgi, C. R.; Pandit-Taskar, N.; Batraki, M.; Warren, N.; Nacca, A.; Smith-Jones, P.; Schwartz, L.; Kelly, W. K.; Slovin, S.; more...
    Clinical Cancer Research (2005)

    Fulltext@MSK | Save
  • Frequency of molecular and PET/CT complete remissions in patients with multiple myeloma after autologous followed by reduced-intensity allogeneic stem cell transplants
    Meeting Abstract

    Zhou, P.; Castro-Malaspina, H.; Papadopoulos, E. B.; Young, J. W.; Miller, K.; Pandit-Taskar, N.; Filippa, D. A.; Fleisher, M.; Comenzo, R. L.
    Blood (2004)

    Fulltext@MSK | Save